Some lung cancer patients benefit from immunotherapy even after disease progression

https://www.eurekalert.org/pub_releases/2017-05/esfm-slc050217.php

Public Release: 4-May-2017
Some lung cancer patients benefit from immunotherapy even after disease progression
Presentations at ELCC 2017
European Society for Medical Oncology

Some advanced lung cancer patients benefit from immunotherapy even after the disease has progressed as evaluated by standard criteria, according to research presented at the European Lung Cancer Conference (ELCC).1 The findings pave the way for certain patients to continue treatment if the disease is not progressing according to new, more specific, criteria.

•••••